Beijing Tianuo Jiancheng Pharmaceutical Technology

Beijing Tianuo Jiancheng Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, focused on the discovery and development of innovative small molecule drugs for metabolic and inflammatory diseases. The company's lead candidate, TN-101, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Tianuo Jiancheng leverages its internal R&D capabilities to build a pipeline of candidates targeting unmet medical needs in the metabolic space. The company aims to provide safer and more effective therapeutic options for patients with chronic metabolic disorders.